Healthcare Facilities company Healthcare Global Enterprises announced Q3FY25 results Revenue: Rs 5,586 million, change +19%, for Q3FY25 YoY. Adjusted EBITDA: Rs 923 million, change +15%, for Q3FY25 YoY. PAT: Rs 70 million, change +23%, for Q3FY25 YoY. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises, said: "HCG has been at the forefront of cancer care, pioneering innovative approaches that integrate multi-disciplinary expertise, advanced molecular and genetic diagnostics, and a huband-spoke patient outreach model. These efforts enable us to deliver highly personalized care, and our strong performance stands as a testament to these strategies. Guided by our vision of making cancer care accessible and affordable, we are committed to reaching over 50% of cancer patients in India through our unique hub-and-spoke model. In addition to our existing Centers of Excellence in Bangalore, Mumbai, Ahmedabad, and Kolkata, we are expanding our footprint by establishing multiple CoEs in Cuttack and Odisha. Unlike traditional multispecialty hospitals, HCG has demonstrated that sustainable, worldclass cancer care outcomes—comparable to or even surpassing those of premier Western centers—are achievable when patients receive the right treatment at the right time, supported by top-tier talent, cutting-edge technology, and state-of-the-art infrastructure. Beyond delivering exceptional care, we have fostered a culture of innovation at every level, prioritizing actionable research, skill enhancement, and continuous learning through our medical and fellowship programs Looking ahead, we envision a future shaped by rapid advancements in genomics, proteomics, and metabolomics—transformative fields that will refine cancer staging and grading while enabling the development of more effective, sustainable therapies. As we continue to push the boundaries of value-based cancer care, our commitment remains unwavering: to redefine cancer treatment and improve patient outcomes on a national scale.” Raj Gore, CEO HealthCare Global Enterprises said: “We are proud to announce highest ever quarterly revenues of Rs 558 crore with a robust growth of 19% and EBITDA standing at Rs 87 crore with a growth of 11% compared to same period last year. Despite being a seasonally weaker quarter, we are proud to have achieved this performance on the basis of improving volumes across modalities. The Oncology business post MG hospital acquisition grew by 24%. Our emerging centers continue to perform well, Kolkata center grew by 40% and South Bombay center grew by 28%. South Bombay center witnessed strong performance despite challenges in international business, which we expect to recover by the upcoming quarter and will be key for the center’s turnaround. We are confident of the robust growth in these centers with improving performance on the back of strong brand creation, quality clinical talent and increased awareness programs for cancer care and diagnosis. During the quarter, we consolidated operations for MG hospital in Vizag. This acquisition has been instrumental in enhancing our footprint in the region, allowing us to further expand our services and strengthen our presence in one of the key markets for cancer care. At HCG, we believe that world-class cancer care should be patient-centric, accessible, and sustainable. Our asset-light model enables us to expand efficiently, ensuring that cutting-edge treatment reaches more people without compromising quality. By integrating advanced technology, precision medicine, and compassionate care, we are not just treating cancer we are redefining the patient experience. As we continue this journey, our focus remains on empowering patients with the best possible outcomes while driving innovation and transforming cancer care across India.” Result PDF